Stockscreener 앱 받기
2.5875
3.37%
-0.0825
Acumen Pharmaceuticals Inc 주식(ABOS)의 최신 뉴스
Acumen Pharmaceuticals to Present Data on Enhanced Brain Delivery™ (EBD™) Technology and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026 - The Manila Times
Acumen to show brain-delivery data and patient insights at AAIC 2026 - Stock Titan
Number of shareholders of Acumen Pharmaceuticals, Inc. – NASDAQ:ABOS - TradingView
Acumen Pharmaceuticals, Inc. commits to advancing targeted therapies for Alzheimer care - Traders Union
Acumen Pharmaceuticals, Inc.(NasdaqGS: ABOS) added to Russell 2000 Index - marketscreener.com
Acumen Pharmaceuticals, Inc.(NasdaqGS: ABOS) added to Russell 2000 Value Benchmark - marketscreener.com
Acumen Pharmaceuticals, Inc.(NasdaqGS:ABOS) added to Russell Small Cap Comp Value Benchmark - marketscreener.com
ABOS Q1 2026 Earnings: EPS Beat Strong as Acumen Advances Alzheimer’s PipelineRevenue Recognition Risk - dars.gov.et
Acumen Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:ABOS) - TradingView
ABOS Forecast — Price Target — Prediction for 2027 - TradingView
Acumen Pharmaceuticals Inc (ABOS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Acumen Pharmaceuticals Inc (ABOS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
JCR Pharmaceuticals Announces That Acumen Pharmaceuticals Has Exercised its Exclusive Option to Develop Therapeutic Candidates for Alzheimer’s Disease, Enabled by J-Brain Cargo® Technology Platform - BioSpace
Acumen Pharmaceuticals Inc (ABOS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Acumen Pharmaceuticals Insider Makes Eye-Catching Stock Move - TipRanks
Acumen Pharmaceuticals director Porter sells $75,239 in stock - Investing.com UK
Acumen Pharmaceuticals director Porter sells $75,239 in stock By Investing.com - Investing.com Australia
Acumen Pharmaceuticals Inc (ABOS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Acumen Pharmaceuticals Inc - TradingKey
Acumen Pharmaceuticals Inc (ABOS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Acumen Pharmaceuticals (ABOS) director sells 32,300 shares after exercising options - Stock Titan
Acumen exercises option for JCR brain technology - grafa.com
Acumen Pharmaceuticals Inc (ABOS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Acumen Pharmaceuticals Inc (ABOS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Acumen Pharmaceuticals Inc (ABOS) Institutional Confidence - TradingKey
Director to sell 13,040 shares (NASDAQ: ABOS) in stock option exercise - Stock Titan
Acumen selects development candidates for Alzheimer’s disease - BioWorld News
Acumen nominates two Alzheimer’s candidates for development - Investing.com UK
Acumen nominates two Alzheimer’s candidates for development By Investing.com - Investing.com South Africa
Acumen Nominates 2 Therapies to Treat Alzheimer’s Disease - Yahoo Finance
ABOS (NASDAQ: ABOS) Form 144 shows proposed sale of 12,800 shares - Stock Titan
Acumen Pharmaceuticals, Inc. advances two new Enhanced Brain Delivery candidates for Alzheimer treatment - Traders Union
Acumen Advances Enhanced Brain Delivery Alzheimer’s Drug Candidates - TipRanks
Acumen Pharmaceuticals nominates two EBD candidates, targets mid-2027 IND with 14-40x brain penetration in NHPs - TradingView
Acumen Pharmaceuticals Nominates Two Development Candidates in Enhanced Brain Delivery Program for Alzheimer's Disease Treatment - Quiver Quantitative
Acumen (NASDAQ: ABOS) advances two EBD Alzheimer’s drug candidates - Stock Titan
Two new antibody designs aim for higher brain delivery in Alzheimer’s - Stock Titan
[144] Acumen Pharmaceuticals, Inc. SEC Filing - Stock Titan
Bank of America Securities Keeps Their Buy Rating on Acumen Pharmaceuticals (ABOS) - The Globe and Mail
Acumen Pharmaceuticals Q1 earnings call highlights - MSN
BofA Securities Maintains Acumen Pharmaceuticals(ABOS.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Acumen Pharmaceuticals director sells $14,272 in company stock By Investing.com - Investing.com Nigeria
Acumen Pharmaceuticals director sells $14,272 in company stock - Investing.com
Insider Sell: Nathan Fountain Sells 6,400 Shares of Acumen Pharm - GuruFocus
Acumen Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Fountain Nathan B - Moomoo
Director Nathan Fountain sells 6,400 Acumen (ABOS) shares at ~$2.23 - Stock Titan
Acumen Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
ABOS Q1 2026 Earnings: Narrower-than-Expected Loss as Phase 2 Readout ApproachesDownward Estimate Revision - newsline.com
Acumen (NASDAQ: ABOS) director equity grant tied to RA Capital funds - Stock Titan
Acumen Pharmaceuticals (NASDAQ: ABOS) director receives RSU and option grants - Stock Titan
Acumen (NASDAQ: ABOS) director granted RSUs and options vesting by 2027 - Stock Titan
Acumen Pharmaceuticals (ABOS) director receives new RSU and option awards - Stock Titan
Acumen Pharmaceuticals (ABOS) grants RSUs and stock options to director - Stock Titan
Acumen Pharmaceuticals (ABOS) director receives RSU and option grants - Stock Titan
Acumen Pharmaceuticals (NASDAQ: ABOS) director awarded RSUs and options - Stock Titan
Acumen Pharmaceuticals (ABOS) director awarded RSUs and options for RA Capital - Stock Titan
Acumen Stockholders Approve Directors and Equity Incentive Plan - TipRanks
Acumen Pharmaceuticals (NASDAQ: ABOS) investors approve equity plan and auditor - Stock Titan
Acumen Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $7.4, Implies 212% Upside - TradingView
Acumen Pharmaceuticals, Inc. pushes research for brain health as dementia numbers climb - Traders Union
Acumen Pharmaceuticals (ABOS) Holds Near Key Support After Slight Upside MoveStop Loss Guidance - dars.gov.et
1.61%
3.59%
자본화:
|
볼륨(24시간):